The Eph receptors are transmembrane proteins that belong to the receptor tyrosine kinases superfamily. Elevated Eph/ephrin expression levels have been associated with angiogenesis and tumor vasculature in many types of human cancers, including breast, lung, and prostate cancers, melanoma, and leukemia. In glioblastoma (GBM), the dysregulated expression of Eph receptors and of corresponding ephrin ligands has been associated with higher tumor grade and poor prognosis making them effective targets for therapeutic drugs. In this study, we describe the GL43.T, an anti-Eph aptamer, able to bind at high-affinity EphB3 and EphB2. Moreover, the GL43.T aptamer inhibits the glioma cell vitality and interferes with ephrine-B1 inhibition of chemotactic serum-stimulated cell migration. GL43.T aptamer represents a promising therapeutic molecule for EphB3-dependent cancers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/nat.2015.0580 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tensile force promotes osteogenic differentiation via ephrinB2-EphB4 signaling pathway in orthodontic tooth movement.
BMC Oral Health
January 2025
Department of Orthodontics, Stomatology School of Jilin University, No. 1500 Qinghua Road, ChaoYang Area, Changchun City, Jilin Province, P.R. China.
Objective: To investigating whether osteogenic differentiation of osteoblasts promoted by tension force (TF) is mediated by ephrinB2-EphB4 signaling.
Methods: TF was applied to MC3T3-E1 cells, then CCK-8 and live/dead staining were used to detect cell proliferation. Levels of osteogenic differentiation-related factors were detected by ALP staining, ARS staining, qPCR and western blot.
Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma.
Proc Natl Acad Sci U S A
January 2025
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
Ependymoma (EPN) is a common form of brain tumor in children, often resistant to available cytotoxic therapies. Molecular profiling studies have led to a better understanding of EPN subtypes and revealed a critical role of oncogenes ZFTA-RELA fusion and EPHB2 in supratentorial ependymoma (ST-EPN). However, the immune system's role in tumor progression and response to therapy remains poorly understood.
View Article and Find Full Text PDFAdvances and current concepts on Eph receptors and ephrins in upper digestive tract cancers.
Front Oncol
January 2025
Department of Pathology, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Erythropoietin-producing hepatocellular (Eph) receptors comprise the largest group of surface receptors and are responsible for cellular signals. Eph/ephrin signaling has been identified to play a role in key cancer development and progression processes, especially in the upper gastrointestinal tract. The Eph/ephrin system has been described as a tumor suppressor in duodenal cancer, while in esophageal, gastric, hepatic, and pancreatic cancer, the system has been related to tumor progression.
View Article and Find Full Text PDFSerum EphA2 as a Promising Biomarker for the Early Detection and Diagnosis of Colorectal Cancer.
Biomolecules
November 2024
Institute of Life Innovation Studies, Toyo University, Tokyo 115-8650, Japan.
Background: EphA2, a receptor-type tyrosine kinase, is overexpressed in several cancers, including colorectal cancer (CRC), and can be detected as soluble EphA2 in serum. This study aimed to investigate the relationship between soluble EphA2 and CRC.
Methods: Serum samples were collected from 65 patients with CRC and 19 healthy individuals.
Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR.
Clin Transl Med
January 2025
Frazer Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Queensland, Australia.
Background: Paediatric sarcomas, including rhabdomyosarcoma, Ewing sarcoma and osteosarcoma, represent a group of malignancies that significantly contribute to cancer-related morbidity and mortality in children and young adults. These cancers share common challenges, including high rates of metastasis, recurrence or treatment resistance, leading to a 5-year survival rate of approximately 20% for patients with advanced disease stages. Despite the critical need, therapeutic advancements have been limited over the past three decades.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!